Several vaccine technologies were evaluated for their abilities to induce anti-human immunodeficiency virus Gag immune responses in rhesus macaques. While no vaccine alone was able to induce broad and strong immune responses, these were achieved by priming with Gag DNA and boosting with Gag protein adsorbed to polylactide coglycolide microparticles. This regimen elicited strong antibodies, helper T cells, and cytotoxic T lymphocytes and thus holds promise as an effective vaccination scheme.
Various immune effector mechanisms are considered to be important for protection against human immunodeficiency virus (HIV). Neutralizing antibodies are thought to be sufficient for protection against challenge in primate models, as passive transfer of various human monoclonal antibodies protects animals from subsequent challenge (16) (17) (18) . In addition, partial protection of macaques was achieved by vaccination with DNA and adjuvant protein vaccines in a priming-boosting regimen, despite depletion of CD8 ϩ T cells at the time of challenge (5) . Similarly, cytotoxic T lymphocyte (CTL) responses are sufficient for partial protection in these models. Such protective CTL responses have been conferred by various vaccine technologies, without the induction of detectable neutralizing antibodies (1, 2, 9, 14, 19, 25, 29) . In addition, certain vaccines based on Gag and/or Pol, which would not be expected to induce virus-neutralizing activity, are partially protective (7, 33, 34) . Finally, depletion of CD8 ϩ T cells through infusion of anti-CD8 antibodies decreases the control of viremia in infected macaques (11, 20, 32) . Thus, both humoral and cellular immunity seem to play a role in protection in primate disease models. The importance of CTLs in protection from AIDS in humans is suggested by the inverse correlation between anti-HIV CTLs and virus load (3, 4, 15, 39) and the high levels of CTLs in chronically exposed, but protected, individuals (8) . In addition to antibodies and CTLs, a robust helper-T-cell response is likely important for the expansion of antigen-specific B-cell and CTL populations and possibly also for provision of antiviral cytokines. Thus, an effective preventative HIV vaccine will likely require the ability to induce broad and potent immune responses, including neutralizing antibodies, CD4
ϩ -Tcell responses, and CTLs.
To this end, various vaccine technologies have been tested as potential HIV vaccines, with various results. In this study, we have compared several distinct vaccine technologies for their abilities to induce anti-HIV immune responses. First, recombinant proteins, by themselves, are not usually particularly immunogenic and require adjuvants for effectiveness. We have found recently that particle-based delivery systems, such as polylactide coglycolide (PLG), are very effective in small-animal models at enhancing immune responses induced by protein-based vaccines (13) . Specifically, anti-HIV Gag antibody responses were increased and, interestingly, CTL responses were induced, which is not typically seen with protein-based vaccines alone. Second, virus-like particles have been found to be effective for inducing antibody and CTL responses in various animal models, including primate models of HIV (21, 23, 26) . To enhance these responses, we have incorporated the adjuvant LTK63, which is a mutated form of Escherichia coli heat-labile enterotoxin that retains adjuvant activity while eliminating toxicity (27) . We have recently shown this adjuvant to be effective at inducing CTLs in mice when it was administered in combination with HIV Gag protein (22) . Finally, DNA vaccines have been demonstrated to be very effective at priming CTL responses in species ranging from mice (6, 10, 36) to humans (31, 37) . Thus, we evaluated each of these distinct technologies (Table 1) for the induction of immune responses in rhesus macaques.
Priming immune responses. First, as one indicator of vaccine potency, anti-Gag antibodies were measured by enzyme-linked immunosorbent assay. As shown in Table 2 , two vaccinations with p55
Gag adsorbed to PLG microparticles (Gag-PLG) (group 2) induced high Gag-specific plasma antibody titers in all four macaques (geometric mean titer [GMT], 16, 200) . After a third dose of Gag-PLG, Gag-specific titers exceeded 100,000 in two of four animals. As expected, Gag protein alone (group 1) was only weakly immunogenic, indicating that the PLG microparticle formulation conferred a substantial benefit (P ϭ 0.03; one-tailed t test), as was seen previously for small animals (31, 35) . Gag virus-like particles (VLP) (group 3) induced low to moderate antibody titers (the GMT was 2,300 at 2 weeks after the second immunization) that were not increased by coadministration of LTK63 (for group 4, the GMT was 400). A third vaccination with VLP or VLP plus LTK63 did not increase Gag-specific antibody titers, indicating the relatively modest immunogenicity of VLP. As has been observed with various other DNA vaccines, vaccination with the pCMVgagmod plasmid DNA (group 5) induced a low level of Gag-specific antibody in only one of four rhesus macaques.
Second, to determine the magnitude of T-cell responses and the spectrum of p55 Gag epitopes recognized by T cells, we utilized recombinant Gag protein and synthetic peptides that were 20 amino acids (aa) in length, overlapped each other by 10 aa, and derived from p55
Gag of HIV-1 SF2 . Beginning 6 weeks after the third immunization, we determined Gag-specific lymphoproliferative responses as a measure of antigenspecific CD4 ϩ 8 Ϫ -T-cell activity (Table 3 ). All four rhesus macaques given Gag-PLG plus LTK63 (group 2) demonstrated proliferative responses to p55
Gag (stimulation index [SI] range, 4 to 138) that were maintained for at least 14 weeks after the third immunization (SI range, 4 to 68). Interestingly, those with the highest proliferative responses (macaques 67 and 72) also had the highest titers of anti-Gag antibodies ( Table 2 ). Gagspecific proliferation was not observed in animals immunized with Gag protein alone (group 1) or VLP (group 3), and only weak responses were observed in two animals immunized with VLP plus LTK63 (group 4) (macaques 65 and 70). Marginal Gag-specific lymphoproliferation was observed in the plasmid DNA-immunized rhesus macaque 14 weeks after the third immunization, with the exception of rhesus macaque 63, which had an SI of 22. Interestingly, this animal was the only one of its group to show a consistently positive antibody titer (Table 2).
Beginning 2 weeks after the second immunization, animals were evaluated for CTL activity by a 51 Cr release assay using peripheral blood mononuclear cells (PBMC) cultured for 8 days in the presence of autologous recombinant vaccinia virus (rVV) gag-pol-infected PBMC or individual pools of overlapping Gag peptides. The cultures were harvested and assayed for cytolytic activity against autologous 51 Cr-labeled B-lympho- Gag protein was administered in saline (group 1) or adsorbed to PLG microparticles (17, 29) and mixed with 0.1 mg of a purified recombinant mutant form of E. coli heat-labile enterotoxin (LTK63) at a final dose of 0.2 mg of Gag (group 2). VLP were produced in and purified from a Tn5 baculovirus expression system (10, 28, 40) and administered in phosphate-buffered saline (group 3) or mixed with 0.1 mg of LTK63 at a final dose of 0.2 mg of VLP (group 4). The pCMV gagmod DNA vaccine, containing a sequencemodified HIV-1 Gag protein from SF2 (40) , was administered at a dose of 1 mg of DNA (group 5).
b At week 41, all four animals primed with Gag DNA were given a booster injection with p55 a Anti-Gag antibodies were measured by enzyme-linked immunosorbent assay. Plasma antibody titers (reciprocal of serum dilution at an absorbance value of 0.5) are rounded to the nearest 100. All animals before vaccination showed no reactivity at the lowest dilution (1:25) .
b Animals were given a booster injection at week 41 of 0. blastoid cell line (B-LCL) targets that were pulsed with Gag peptide pools. As shown in Table 4 , immunization with Gag protein (alone) did not induce CTLs, with the exception of a weak response (macaque 74) (19% Gag-specific 51 Cr release maximum) in a single instance. Likewise, only one of the four animals (macaque 72) that was vaccinated with Gag-PLG microparticles plus LTK63 showed CTL activity and only after the third immunization; however, this animal had mistakenly also received a dose of VLP at the time of its third immunization. Hence, we cannot be certain that any CTLs were induced by the p55
Gag -PLG plus LTK63 vaccine alone. Gagspecific CTL activity was detected in approximately half of the animals vaccinated with VLP or VLP plus LTK63 and in all four rhesus macaques vaccinated with plasmid DNA. With the exception of macaque 72, all animals that showed CTL activity 2 weeks after the third immunization maintained that activity for at least 12 additional weeks (14 weeks after the third immunization) (Table 4) . Moreover, when the DNA-immunized rhesus macaques were evaluated 23 to 24 weeks after the third dose, all four animals remained CTL positive. In general, it appears that CTL activity was boosted by the third immunization, as was seen by higher levels of lytic activity at 6 and 14 weeks after the third immunization than at 2 weeks after the second immunization (Fig. 1) . However, CTL responses eventually declined, as was seen by lower levels of lytic activity by 23 weeks after the third immunization. Because the 51 Cr-labeled B-LCL targets were pulsed with peptide pools spanning distinct portions of the entire Gag protein sequence, we could determine whether Gag vaccines induced CTL populations that reacted with single or multiple discrete epitopes. As shown in Table 5 , Gag peptide pools 1, 2, 4, 5, and 8 contained 
a Cytolysis was measured in peptide-pulsed or rVV gag-pol-infected autologous B-LCL that had been stimulated with PBMC treated with Gag peptides or infected with rVV gag-pol. All animals showed no Gag-specific 51 Cr release before vaccinations. ϩ, Ն10% Gag-specific 51 Cr release at two consecutive effector-to-target ratios; no ϩ or Ϫ, data not determined.
b Rhesus macaque 72 was also given VLP at the time of the third immunization. epitopes recognized by one or more of the CTL-positive rhesus macaques. In addition, two of the plasmid-immunized rhesus macaques (macaque 63 and macaque 77) contained CTLs that reacted with three separate Gag peptide pools. Further analysis using target cells pulsed with individual peptides revealed the presence of multiple epitopes. Three peptides in pool 1 (p55 Gag aa 1 to 80) and at least two peptides in pool 5 (p55 Gag aa 194 to 263) were recognized; however, only a single peptide in pool 4 (p55 Gag aa 254 to 323) was identified. In the case of DNA immunization, priming of Gag-specific CTLs in vivo resulted from the CTL precursor recognition of Gag epitopes derived from the processing and presentation of endogenously synthesized Gag. However, CTL effectors were derived by culture with synthetic Gag peptides and were assayed against peptide-pulsed autologous target cells. Nevertheless, peptidestimulated CTLs derived from the PBMC of DNA-immunized rhesus macaques were also able to recognize and lyse target cells that expressed Gag endogenously (data not shown).
Broadening of immune responses by priming with DNA and boosting with Gag-PLG. Although plasmid DNA was the best of the vaccines at inducing CTLs, it is likely that a successful HIV vaccine must also induce CD4 ϩ T cells with the capacity for providing help for proliferation and differentiation of HIVreactive CTLs and B cells (12, 28, 30) . To determine if lymphoproliferative and antibody responses could be increased in the plasmid DNA-immunized rhesus macaques, the animals were given a single dose of Gag protein adsorbed to PLG microparticles at week 41. In this case, the LTK63 adjuvant was not included since it did not enhance the proliferative or antibody responses after immunization with VLP. Lymphoproliferation assays were performed at 2 and 6 weeks after the booster dose. After protein boosting, four DNA-primed animals had increased Gag-specific lymphoproliferation and concomitant increases in antibodies. For the group, the geometric mean SI (Table 3) increased from 5 (week 22) to 15 to 17 (weeks 43 and 49) (P ϭ 0.07; one-tailed t test). Likewise, Gag antibody titers (Table 2) exhibit Gag-specific antibodies after DNA immunization alone, showed the highest levels of antigen-specific proliferation and antibodies after the boosting.
Because the animals primed with the Gag-PLG plus LTK63 protein-adjuvant combination had strong lymphoproliferative and antibody responses, they were given a boosting dose at week 41. As shown in Tables 2 and 3 , 2 weeks after the fourth immunization with Gag-PLG plus LTK63, all four animals showed strong proliferative responses (SI range, 13 to 110) and high antibody titers (5,800 to 51,700). These responses changed very little by 6 weeks after the fourth immunization. Using the Gag peptide pools to elicit lymphoproliferation, we identified several stimulatory peptide pools, and in animals 67 and 72 we observed proliferation in response to several distinct pools, indicating a polyepitope-specific repertoire (data not shown). A limited analysis of the frequency and phenotype of the Gag-specific T-cell response by flow cytometry demonstrated gamma interferon and tumor necrosis factor alpha production with a frequency of up to 0.8% of CD4 T cells (data not shown).
The vaccine technologies that we evaluated for this rhesus macaque study included recombinant protein administered with a microparticle-based delivery system (PLG), LTK63 adjuvant, VLP, and plasmid DNA. Each of these technologies was chosen for its potential to overcome the hurdle of priming CTL responses without the use of a live vector system (based on results of small-animal studies) (13, 21-24, 26, 35, 40) , thereby providing broad immune responses with a relatively simple vaccine. However, as is clear from the data reported here, these technologies had very different abilities to prime immune responses in rhesus macaques, with none of them alone being able to prime broad and strong immune responses. Gag DNA was the most potent technology for CTL induction, while Gag protein adsorbed to PLG microparticles was best for antibody and helper-T-cell responses. These results suggested possible synergy between the DNA and Gag-PLG vaccine technologies for providing strong and broad immune responses. Indeed, priming with Gag DNA and boosting with Gag-PLG achieved high levels of anti-Gag antibodies, helper T cells, and CTLs. It is likely that these broad responses were due, at least in part, to the complementary nature of the two technologies. DNA vaccines produce small amounts of antigen expressed appropriately for efficient priming of CTLs, and Gag-PLG provides a bolus of antigen delivered efficiently for the induction of robust antibodies and helper T cells. The strong synergy with Gag DNA priming and boosting with Gag protein adsorbed to PLG microparticles suggests the utility of this vaccine strategy for providing broad and strong immune responses without the need for a live vector system. Furthermore, this strategy is amenable to additional enhancement with improved DNA vaccine delivery, as has been recently observed (24, 35, 38) . 
